Nxera Pharma Co., Ltd. (TYO: 4565)
Market Cap | 92.96B |
Revenue (ttm) | 29.28B |
Net Income (ttm) | -3.71B |
Shares Out | 89.90M |
EPS (ttm) | -42.09 |
PE Ratio | n/a |
Forward PE | 48.10 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 210,000 |
Open | 1,055.00 |
Previous Close | 1,052.00 |
Day's Range | 1,037.00 - 1,056.00 |
52-Week Range | 1,030.00 - 1,826.00 |
Beta | n/a |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Feb 10, 2025 |
About Nxera Pharma
Nxera Pharma Co., Ltd. develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a novel formulation for the treatment of oropharyngeal candidiasis; and PIVLAZ for the treatment of cerebral vasospasm indications. The company’s development products pipeline consists of HTL0039732 for imm... [Read more]
Financial Performance
Financial StatementsNews
Nxera Pharma Enrolls First Insomnia Patient in its Phase 3 Clinical Trial of Daridorexant in South Korea
Tokyo, Japan and Cambridge, UK, 5 December 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – today announces randomization of the f...
Nxera Pharma's Partner Centessa Initiates Phase 2 Trial with ORX750, a Novel Orexin Receptor 2 (OX2R) Agonist
Tokyo, Japan and Cambridge, UK, 13 November 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – notes that Centessa Pharmaceuticals h...
Nxera Pharma and Antiverse Enter Collaboration To Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AI
Tokyo, Japan and London and Cardiff, UK, 5 November 2024 – Nxera Pharma (“Nxera”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – and Antiverse, a techbio company designing antibodies fo...
Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2024
Tokyo, Japan and Cambridge, UK, 1 November 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – provides an update on operational acti...
Nxera Pharma Wins Biotech Company of the Year and Financing Deal of the Year at the Citeline Japan Awards 2024
Tokyo, Japan and Cambridge, UK, 23 October 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – is pleased to announce that it has won...
Nxera Pharma to Host R&D Day 2024
Nxera Pharma Co., Ltd. will hold an R&D Day on 6 November 2024 at 16:30 JST. The meeting will be held virtually via Zoom webinar. Please click here to pre-register for the event.
Nxera Pharma Appoints Experienced Commercial R&D Executive Makoto Sugita as Chief Medical Officer and President of Nxera Pharma Japan
Tokyo, Japan and Cambridge, UK, 1 October 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – today announces the appointment of Dr. ...
Nxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ™ in Japan
Tokyo, Japan and Cambridge, UK, 1 October 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – announces that Nxera Pharma Japan Co., ...
Nxera Pharma Receives Approval of QUVIVIQ (daridorexant) 25 and 50 mg in Japan for the Treatment of Insomnia
Tokyo, Japan and Cambridge, UK, 24 September 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – announces that Nxera Pharma Japan Co...
Nxera Pharma's Partner Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
Tokyo, Japan and Cambridge, UK, 11 September 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – notes the announcement by Centessa P...
Nxera Pharma to Receive US$35 Million from Neurocrine Biosciences upon Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568
Tokyo, Japan and Cambridge, UK, 2 September 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – announces that it will receive a US$3...
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2024
Tokyo, Japan and Cambridge, UK, 9 August 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second quar...
Nxera Pharma Webinar Presentation for Q2 FY2024 Financial Results
Tokyo, Japan and Cambridge, UK, 9 July 2024 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) will announce its earnings results and present operational highlights for the 6 months ended 30 June 2024 on Frid...
Nxera Pharma Receives US$10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone
Tokyo, Japan and Cambridge, UK, 27 June 2024 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565), announces that it has reached an important R&D milestone under its multi-target discovery collaboration with Ab...
Nxera Pharma Publishes its Annual and ESG Reports for the Year ended 31 December 2023
Tokyo, Japan and Cambridge, UK, 18 June 2024 – Nxera Pharma (“Nxera” or “the Company”; TSE 4565), today announces the publication of its Annual Report and its Environment, Social & Governance (ESG) Re...
Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals
Tokyo, Japan and Cambridge, UK, 30 May 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) today announced that it expects to receive $4.6 million in milestone payments from Centessa Pharmaceuti...
Nxera Pharma and PrecisionLife Expand Strategic R&D Partnership into New Therapeutic Area
Tokyo, Japan, Oxford and Cambridge, UK, 30 May 2024 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) and PrecisionLife, the Causal AI precision medicine company, today announce the expansion of their strate...
Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2024
Tokyo, Japan and Cambridge, UK, 9 May 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter ...
Nxera Pharma: Notice of Issuance of New Shares Under the Restricted Stock Unit (RSU) Plan and Determination of Payment Amount and Other Matters of Issuance of New Shares Under Previous Years' RSU Plan
Tokyo, Japan and Cambridge, UK, 17 April 2024 – Nxera Pharma Co. Ltd (“Nxera” or “the Company; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – announces that it has decided to issue new ...
Nxera Pharma Announces Exclusive Supply and Distribution Agreement with Handok for PIVLAZ™ in South Korea
Tokyo, Japan and Cambridge, UK, 1 5 April 2024 – Nxera Pharma Co. Ltd (“Nxera” or “the Company; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – today announces that its operating busines...
Nxera Pharma is the New Name for Sosei Group
Tokyo, Japan and Cambridge, UK, 1 April 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – is pleased to announce the launch of its n...
Sosei Group: Notice of Change of Corporate Name to Nxera Pharma and Change of Location of Head Office
Tokyo, Japan and Cambridge, UK, 16 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565), today announces that at a meeting held on 15 February 2024, its Board of Dire...
Sosei Group Announces Appointment of Experienced Pharmaceutical Executive Toshihiro Maeda as Chief Operating Officer
Tokyo, Japan and Cambridge, UK, 5 January 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) today announces the appointment of Mr. Toshihiro Maeda as Chief Operating Office...
Sosei Group Announces Marketing Approval for PIVLAZ™ (clazosentan sodium) 150 mg in South Korea
Tokyo, Japan, Seoul, South Korea, and Cambridge, UK, 7 December 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) today announces that PIVLAZ™ (clazosentan sodium) 150 mg h...
Sosei Heptares Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2023
Tokyo, Japan and Cambridge, UK, 10 November 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated resu...